TRANSITION TO BEGIN ISLET NEOGENESIS U.K. PHASE I TRIAL.Transition Therapeutics Inc. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension VENTURE:TTH TTH The Tragically Hip (band) TTH Tiger Tree Hash TTh Tuesdays and Thursdays TTH Team Tvis Holstebro (Danish Handball Club) TtH Tex to Html Translator TTH Tactical Transport Helicopter ) ("Transition"), Toronto, Canada, has received approval to begin a dose escalating Phase I human trial in the United Kingdom of its Islet islet /is·let/ (-lit) an island. islets of Langerhans irregular microscopic structures scattered throughout the pancreas and comprising its endocrine portion. Neogenesis ne·o·gen·e·sis n. Regeneration of tissue. ne  o·ge·net ic adj. Therapy (I.N.T.(TM)), a therapy that has been demonstrated in pre-clinical studies to be effective at stimulating the body to regenerate insulin producing cells and reducing diabetic symptoms. "The approval of the Phase I represents a significant milestone for the company and demonstrates that Transition is focused on rapidly moving products to the clinic." said Tony Cruz, chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Transition Therapeutics Inc. Transition expects the trial to be complete by early 2003. Transition believes that I.N.T. represents a new paradigm New Paradigm In the investing world, a totally new way of doing things that has a huge effect on business. Notes: The word "paradigm" is defined as a pattern or model, and it has been used in science to refer to a theoretical framework. in the treatment of diabetes because it consists of a simple, non-invasive regenerative therapy that mimics the normal development of insulin producing cells. I.N.T. is a short course of injections of two well-defined human growth factors that stimulates the body to regenerate insulin producing cells that are damaged or destroyed in those with insulin-dependent diabetes in·su·lin-de·pen·dent diabetes n. See diabetes mellitus. . This treatment has the potential of reducing, and in some case eliminating, the need for insulin injections. The initiation of Phase I human trials for I.N.T. has enabled the company to commence closure of its laboratory facility in Woburn, Mass. and reduce its headcount that was dedicated to the pre-clinical development of I.N.T. Senior officers affected by the closure included Dr. Stephen Brand, Dr. Sheila Magil, and Phil Shapiro. Brand will remain associated with Transition in an advisory capacity. About Transition Therapeutics Transition Therapeutics Inc. is a publicly listed biopharmaceutical company developing innovative therapeutics focusing on the treatment of multiple sclerosis, diabetes and restenosis. Transition offers a deep product portfolio and a strong management team with expertise in product development. Transition's management intends to continue to build shareholder value by rapidly and cost effectively advancing products from discovery to the clinic and licensing to corporate partners. For more information, call 416/260-7770 Ext. 224 or visit http://www.transitiontherapeutics.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion